• Co-Diagnostics’ third-quarter 2026 net loss widened 7% year over year to $6.31 million.
• Revenue jumped 95% year over year to $282,881, while operating expenses fell 12% to $6.25 million.
• Cash totaled $714,803 at September 30; subsequent senior secured convertible debt financing provided approximately $2.1 million before other transaction expenses.
• Regulators are reviewing the point-of-care tuberculosis test in India and the Flu A/B & RSV test in the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93673) on November 10, 2026, and is solely responsible for the information contained therein.